We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About TISSIUM Stock

Invest in or calculate the value of your shares in TISSIUM or other pre-IPO companies through EquityZen's platform.

Get Started

TISSIUM Stock (TIUM)

TISSIUM develops biodegradable sealants and adhesives for wound closure in the field of minimally-invasive surgery.

About TISSIUM Stock

Founded

2013

Industries

Software, Artificial Intelligence, Data and Analytics

TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues, and deliver on-demand wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC, and CapDecisif Management.

TISSIUM Press Mentions

Stay in the know about the latest news on TISSIUM

TISSIUM Management

Leadership team at TISSIUM

Co-Founder & Chairman of the Scientific & Clinical Advisory Boards

Jeff Karp

Board Member

Hongjie Hu

Locked Features

Join now and verify your accreditation status to gain access to:

  • TISSIUM current valuation
  • TISSIUM stock price
  • Available deals in TISSIUM and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

Trading TISSIUM Stock

How to invest in TISSIUM stock?

Accredited investors can buy pre-IPO stock in companies like TISSIUM through EquityZen funds. These investments are made available by existing TISSIUM shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell TISSIUM stock?

Shareholders can sell their TISSIUM stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."